| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| HCQS | IPCA | Sai Pharmaceuticals Ltd. | 200mg | 30 | Tablet | per tablet | KES 719.00 |
| Hydroxychloroquine More info | |
|---|---|
| Mode Of Action | May inhibit meroThey are also thought to inhibit heme polymerase activity resulting in accumulation of free heme, which is toxic to the parasites. |
| Drug Indication | It is given orally in treatment of systemic and discoid lupus erythematosus and rheumatoid arthritis. It is sometimes used where chloroquine is indicated. It has simi-lar S/Es as chloroquine though it is thought to cause less ocular toxicity. |
| Precautions | Hepatic disorders, alcohol, renal insufficiency, hepatotoxic drugs, history of myasthenia gravis, avoid operation of machinery, regular eye inspections on prolonged use, psoriasis. |
| Contra-Indications | Severe GI, neurological and blood disorders, pregnancy, hepatotoxic drugs, epilepsy, general psoriasis. |
| Side Effects | GI disturbances, skin eruptions, pru-ritis, headache, visual disturbances, hearing disorders, mental changes, blood dyscra-sias, hair loss, hair pigment bleach, blue-black pigmentation mucus membrane and skin, photosensitivity, tinnitus, myopathy, neuropathy, hypotension. ECG changes. |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Anti-Malarials |